Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GTB-3550 · CD16

Fusion protein · Immune activation · developed by ImmunityBio

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is GTB-3550?

GTB-3550 is a fusion protein composed of CD16, IL-15, and CD33 domains. It is being studied in high-risk myelodysplastic syndromes, acute myelogenous leukemia, systemic mastocytosis, and mast cell leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CD16, CD16/IL-15/CD33
Drug type
Fusion protein
Mechanism
Immune activation
Pathways
antibody-dependent cellular cytotoxicity
Therapy area
Oncology
Developer
ImmunityBio, Inc.
In trials of
GTBP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
E5GE91Q5FX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03214666 Phase 1/2 High-risk Myelodysplastic Syndromes Terminated GTBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myelogenous LeukemiaHigh-risk Myelodysplastic SyndromesMast Cell LeukemiaSystemic Mastocytosis

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.